Summary
The relationship between cell kinetics and hormonal status and the relevance of the cell kinetic variable on success of hormonetherapy in estrogen receptor positive (ER+) breast tumors were analyzed in patients with advanced disease. Cell kinetics were evaluated as in vitro3H-thymidine labeling index (LI), and estrogen receptor (ER) and progesterone receptor (PgR) with the dextran-coated charcoal technique. The analyses performed on primary tumor or soft tissue metastases from 52 patients showed a general association between the presence of hormone receptors and low proliferative activity, or the absence of receptors and high proliferative activity (ER and L.I.: p>0.05; PgR and L.I.: p = 0.05). However, hormonal status and cell kinetic status were unrelated in about 40% of the cases. Clinical response to additive hormonotherapy was analyzed in relation to pretreatment LI in 29 patients with ER+ tumors. Time to reach maximum response was significantly longer in slow than in fast proliferating tumors, but complete remission was reached in 88% of slow proliferating tumors compared to only 46% of fast proliferating tumors. These preliminary results show that ER+ fast proliferating tumors largely escape hormonal control, and if confirmed on larger series, could identify cell kinetics as an important tool to select patients who will benefit from hormonal treatment.
References
De Sombre E: Hormone receptors, prognosis and therapy. Clinics in Oncology 1: 191–213, 1986
McGuire WL, Osborne CK, Clark GM, Knight WA III: Steroid hormone receptors and carcinoma of the breast. Am J Physiol 243: 99–102, 1982
Maass H, Jonat W, Stolzenbach G, Trams G: The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer. Cancer 46: 2835–2838, 1980
Pertschuk LP, Eisenberg KB, Carter AC, Feldman JG: Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Cancer 55: 1513–1518, 1985
Silvestrini R: The cell kinetics of breast cancer. In: Bonadonna G (ed) Breast Cancer, Diagnosis and Management. Wiley & Sons Ltd, 1984, pp 5–13
Antoniades K, Spector H: Quantitative estrogen receptor values and growth of carcinoma of the breast before surgical intervention. Cancer 50: 793–796, 1982
Meyer JS, Rao BR, Stevens SC, White WL: Low incidence of estrogen receptor in breast carcinoma, with rapid rates of cellular replication. Cancer 40: 2290–2298, 1977
Straus MJ, Moran R, Muller RE, Wotiz HH: Estrogen receptor heterogeneity and the relationship between estrogen receptor and the tritiated thymidine labeling index in human breast cancer. Oncology 39: 197–200, 1982
Bertuzzi A, Daidone MG, Di Fronzo G, Silvestrini R: Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Res Treat 1: 253–262, 1981
Kute TE, Muss HB, Anderson D, Crumb K, Miller B, Burns D, Dube LA: Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer. Cancer Res 41: 3524–3529, 1981
Moran RE, Black MM, Alpert L, Straus MJ: Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer. Cancer 54: 1586–1590, 1984
EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9: 379–381, 1973
Paradiso A, Tommasi S, Schittulli F, De Lena M: Trattamento ormonale sequenziale alternato nel carcinoma mammario in fase avanzata. Studio Randomizzato Tumori 72: 723, 1986
Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 8: 1982–1987, 1985
Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986
Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation and its relationship to clinical features and relapse in breast cancer. Cancer 48: 974–979, 1981
Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and responses in human breast cancer. J Natl Cancer Inst 62: 513–517, 1979
Silvestrini R, Daidone MG, Canova S, Valagussa P, Bonadonna G: Is there any role for cell kinetics as a predictor of clinical outcome in locally advanced breast cancer? Breast Cancer Res Treat 6: 164, 1985
Meyer JS, Lee JY: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness and duration of survival. Cancer Res 40: 1890–1896, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paradiso, A., Lorusso, V., Tommasi, S. et al. Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer. Breast Cancer Res Tr 11, 31–36 (1988). https://doi.org/10.1007/BF01807555
Issue Date:
DOI: https://doi.org/10.1007/BF01807555